Vifor Pharma, a pharmaceutical company, agreed to acquire Sanifit Therapeutics, a biopharmaceutical company, for $423m. “Today’s exciting announcement helps us to build on our strong nephrology pipeline to help end-stage kidney disease patients globally. Through the acquisition of Sanifit and its lead compound SNF472, we will further expand our growing nephrology pipeline into vascular calcification, a major cause of morbidity and mortality in patients with end-stage kidney disease," Abbas Hussain, Vifor Pharma CEO.